Volume 20, Issue 80 (7-2012)                   zumsj 2012, 20(80): 1-11 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Dakterzada F, Mohabati Mobarez A, Habibi Roudkenar M, Forouzandeh M. Cloning and Expression of N-teminal Domain of Pseudomonas aeruginosa Flagellin and Evaluation of Antibodies Raised against it on Motility Inhibition of Pseudomonas aeruginosa. zumsj. 2012; 20 (80) :1-11
URL: http://zums.ac.ir/journal/article-1-1826-en.html
Abstract:   (26968 Views)

Background and Objective: Pseudomonas aeruginosa is an opportunistic pathogen that causes severe and lethal infections in immunocompromised individuals. This bacterium possesses a single polar flagellum. Flagellum and its subunit Flagellin play important roles in the pathogenesis of P. aeruginosa. Flagellin induces immune responses by interaction of its N-terminal domain with TLR-5. Our main aims of this study were cloning and expression of N-terminal domains of flagellin and evaluation of antibodies raised against it on motility inhibition of P. aeruginosa. Material and Methods: The DNA sequence coding for the first 161 amino acids of flagellin was PCR amplified and cloned into a pET-28a expression vector. Recombinant protein was over expressed in BL-21(DE3), and purified by Ni-NTA resin. The immune reactivity of recombinant truncated flagellin was evaluated by Western blotting. The recombinant protein was injected into a rabbit and antibodies raised against it were evaluated for the cell motility inhibition of P. aeruginosa 8821M. Results: The N-terminal domain of Flagellin was successfully overexpressed in Escherichia coli BL-21(DE3) host strain. Anti-native and anti-N-terminal flagellin antibodies reacted with the recombinant protein. Motility inhibition assay demonstrated that polyclonal antiserum against N-teminal flagellin is able to inhibit the motility of P. aeruginosa 8821M. Conclusion: The N-terminal domain of flagellin may be used for development of a new recombinant vaccine against P. aeruginosa infections.

Full-Text [PDF 274 kb]   (2751 Downloads)    
Type of Study: Applicable | Subject: General
Received: 2012/07/11 | Accepted: 2014/06/21 | Published: 2014/06/21

Add your comments about this article : Your username or Email:
CAPTCHA code

© 2019 All Rights Reserved | ZUMS Journal

Designed & Developed by : Yektaweb